Stockscreener 앱 받기
3.6102
3.26%
0.1402
전일 마감가:
$3.47
열려 있는:
$3.61
하루 거래량:
798.16K
Relative Volume:
0.19
시가총액:
$374.50M
수익:
-
순이익/손실:
$-165.67M
주가수익비율:
-1.6354
EPS:
-2.2075
순현금흐름:
$-113.29M
1주 성능:
+1.51%
1개월 성능:
-19.30%
6개월 성능:
+1.51%
1년 성능:
+95.80%
1일 변동 폭
$3.47
$3.67
1주일 범위
$3.40
$3.67
52주 변동 폭
$1.80
$6.42
Larimar Therapeutics Inc Stock (LRMR) Company Profile
명칭
Larimar Therapeutics Inc
전화
844-511-9056
주소
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
Compare LRMR vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LRMR
Larimar Therapeutics Inc
|
3.605 | 360.47M | 0 | -165.67M | -113.29M | -2.2075 |
VRTX
Vertex Pharmaceuticals Inc
|
441.38 | 110.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
629.64 | 66.53B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
829.50 | 50.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.38 | 39.45B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
152.28 | 32.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-29 | 개시 | Truist | Buy |
| 2024-10-16 | 개시 | Oppenheimer | Outperform |
| 2024-10-03 | 개시 | Wedbush | Outperform |
| 2024-10-02 | 개시 | H.C. Wainwright | Buy |
| 2024-09-04 | 개시 | Robert W. Baird | Outperform |
| 2024-04-03 | 개시 | Leerink Partners | Outperform |
| 2023-11-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-10-19 | 개시 | Guggenheim | Buy |
| 2022-02-15 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-02-10 | 개시 | JMP Securities | Mkt Outperform |
| 2021-02-01 | 개시 | William Blair | Outperform |
모두보기
Larimar Therapeutics Inc 주식(LRMR)의 최신 뉴스
LRMR Initiates Coverage by JP Morgan -- Rating Set at Overweight - GuruFocus
JPMorgan initiates Larimar Therapeutics stock at Overweight - Investing.com
JPMorgan initiates Larimar Therapeutics stock at Overweight By Investing.com - Investing.com Australia
Certain Pre-Funded Warrants of Larimar Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2026. - marketscreener.com
Larimar Therapeutics Stock Slumps Pre-market Over High Anaphylaxis Rate In Drug Study - MSN
[Form 4] Larimar Therapeutics, Inc. Insider Trading Activity - Stock Titan
Larimar Therapeutics (LRMR) entity tied to director receives 55,150 stock options - Stock Titan
Larimar Therapeutics (LRMR) awards 55,150 stock options to director - Stock Titan
Larimar Therapeutics (LRMR) director receives 55,150 stock options grant - Stock Titan
Larimar Therapeutics (LRMR) director awarded 55,150 stock options at $3.33 strike - Stock Titan
Larimar Therapeutics (LRMR) director gets 55,150 stock options at $3.33 strike - Stock Titan
Larimar Therapeutics stockholders approve board elections and share increase By Investing.com - Investing.com Nigeria
Larimar Therapeutics stockholders approve board elections and share increase - Investing.com
Larimar Shareholders Approve Governance and Capital Structure Changes - TipRanks
Larimar Therapeutics (NASDAQ: LRMR) holders back big authorized share increase - Stock Titan
LRMR Maintained by Wedbush -- Price Target Lowered to $12.00 - GuruFocus
Wedbush Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Larimar Therapeutics Price Target Cut to $12.00/Share From $13.00 by Wedbush - Moomoo
Larimar Therapeutics (LRMR) surges on FDA breakthrough therapy designation - MSN
Wedbush Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Cuts Target Price to $12 - Moomoo
Number of shareholders of Larimar Therapeutics, Inc. – NASDAQ:LRMR - TradingView
Wedbush Adjusts Larimar Therapeutics Price Target to $12 From $13, Maintains Outperform Rating - Moomoo
Larimar Details Q1 Results and Nomlabofusp Regulatory Progress - The Globe and Mail
Exploring US High Growth Tech Stocks This May 2026 - Yahoo Finance
Citizens reiterates Larimar Therapeutics stock rating on FDA progress By Investing.com - Investing.com South Africa
Citizens reiterates Larimar Therapeutics stock rating on FDA progress - Investing.com India
Larimar Therapeutics, Inc. Stock 12‑Month Price Target Cut to $15.88, Implies 287% Upside - TradingView
LARIMAR THERAPEUTICS (LRMR) Advances towards Friedreich's Ataxia Treatment Approval - GuruFocus
Blue Owl (NASDAQ: LRMR) discloses 9.99% position totaling 10.74M shares - Stock Titan
Larimar Therapeutics (LRMR) lifts cash to $200M as FDA grants Breakthrough status - Stock Titan
Larimar Therapeutics 1Q Research and Development Expenses $25.0M >LRMR - Moomoo
Larimar Therapeutics Advances Nomlabofusp for Friedreich’s Ataxia with Rolling BLA Submission and Strong Q1 2026 Financials - Minichart
Larimar Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
LRMR: Nomlabofusp shows strong efficacy and safety in FA, targeting 2027 U.S. launch - TradingView
Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update - The Manila Times
Larimar: Q1 Earnings Snapshot - KTVB
Larimar Therapeutics (LRMR) boosts cash, eyes 2027 launch for FA therapy - Stock Titan
BRIEF-Larimar Therapeutics Q1 Net Income USD -29.613 Million - TradingView
MSN Money - MSN
TradingKey - TradingKey
LRMR (Larimar Therapeutics) Q4 loss widens 41% miss as drug development costs climb; shares edge lower.Investment Signal Network - newser.com
LRMR SEC FilingsLarimar Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Larimar Data Support Surrogate Endpoint for Nomlabofusp Approval Path - MyChesCo
Analysts Offer Insights on Healthcare Companies: Stryker (SYK) and Larimar Therapeutics (LRMR) - The Globe and Mail
Larimar Therapeutics, Inc. $LRMR Shares Acquired by AIGH Capital Management LLC - MarketBeat
LRMR Forecast, Price Target & Analyst Ratings | LARIMAR THERAPEUTICS INC (NASDAQ:LRMR) - ChartMill
Millennium Management (LRMR) reports 3.5% ownership; 3,625,278 shares - Stock Titan
Larimar Therapeutics Publishes Cross-Species Findings - GlobeNewswire
Larimar Therapeutics stock dips after pricing $100M share offering - MSN
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Larimar Therapeutics Inc (LRMR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Larimar Therapeutics Inc 주식 (LRMR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Hamilton Thomas Edward | Director |
Feb 27 '26 |
Buy |
5.00 |
100,000 |
500,000 |
664,798 |
| THOMAS FRANK E | Director |
Feb 27 '26 |
Buy |
5.00 |
5,000 |
25,000 |
7,000 |
| SHERMAN JEFFREY W | Director |
Feb 27 '26 |
Buy |
5.00 |
5,000 |
25,000 |
5,000 |
| Flynn James E | Director |
Jul 31 '25 |
Buy |
3.20 |
9,375,000 |
30,000,000 |
9,538,945 |
0.67%
1.91%
자본화:
|
볼륨(24시간):